Press release

2 Mar 2021 London, GB

EY invests in growth of Life Sciences business

EY invests in growth of Life Sciences business

EY today announces that it has expanded its Life Sciences practice with the appointment of two new Partners, four Associate Partners and three Directors in the UK and globally. Over the last few months, EY has hired an additional 37 people, ranging from Consultant level to Senior Manager level, making it a leading commercial team in Europe. 

The Life Sciences Commercial Access practice focusses on supporting clients to bring pharmaceutical products and medicines from research and development stages through to commercial use, advising on drug development, medical and digital technologies. This also includes clinical trials, market entry, regulations, marketing, medical affairs, pricing and market access for innovative drugs and interventions. The team will work across EY’s Consulting, Strategy and Transactions, Tax and Assurance capabilities to offer clients a one-stop solution to take products to market.

Dr Ravi Degun joins EY as a Partner in London to lead the Life Sciences Commercial Access practice for EY globally. He is a specialist in commercial launch, portfolio strategy and market access. Ravi has supported biopharma and med-tech clients globally across different therapeutic areas including most recently COVID-19 interventions. Ravi has worked in academia, government research and consulting. He has a PhD. in Immunology and Vaccine Development, from the GKT Medical School, King’s College London, and a B.Sc.(Hons) in Molecular Biology & Genetics. To complement his scientific background, Ravi studied business strategy at Tanaka Business School, Imperial College (London) and London Business School.

Dr Mark Chalmers also joins as Partner and is based in Dublin. He specialises in global commercial strategy, including international pricing and market access for pharmaceutical and biotech companies. Mark brings global experience in healthcare systems and health technology assessments with a deep knowledge of oncology, rare diseases, cell and gene-based therapies. Mark has a PhD in Pharmacology & Molecular Biology from the University of Cambridge and a B.Sc. in Pharmacology with Industrial Experience from the University of Edinburgh. 

The four Associate Partners that have joined the firm are Dr Alex Charitou, Stuart MacGregor, Dr Nina Marinsek and Dr Maurice Perrinjaquet and the three Directors are  Nicholas Georgitseas, Dr Binara Rupasinghe and Dr Richard Schlegel. These new appointments will be based across EY offices in the UK, Ireland and Germany.

Dan Mathews, EY EMEIA Life Sciences Market Lead, said: “It is with great pleasure that we are appointing Ravi, Mark and 44 new colleagues to join the EY team, bringing a wealth of global experience and in-depth market knowledge. This is a significant and timely investment in our Life Sciences consulting capability.

“EY already has deep sector expertise across healthcare, life sciences and wellness. With the expansion of our team, we’re bringing together some of the best industry talent. Combined with our cross-sector and cross-service line solutions and our global network, we will be able to offer clients a broader range of services to support their speed, growth and scale to market.”

Benoit Laclau, EY UK&I Managing Partner for Consulting, said: “We have recruited a wonderful set of people who bring a wealth of experience to EY and will further strengthen our life sciences practice across the UK, Ireland and globally. This is an important signal of our investment into this critical sector and will enable us to expand the range of services we can offer our clients at this time.”

Ravi Degun said: “I’m thrilled to be taking on this role at such a challenging and critical time for the life sciences industry. We’re building a formidable team and I look forward to working as part of EY’s Consulting business in Life Sciences to drive real progress in our field.”

Mark Chalmers said: “This is a crucial moment in time for the industry. I am delighted to join the EY team to further build the commercial access team and support clients in developing and launching new drugs to market.”